The Therapeutic Potential of Imidazole or Quinone-Based Compounds as Radiosensitisers in Combination with Radiotherapy for the Treatment of Head and Neck Squamous Cell Carcinoma

Mitochondrial Inhibitor Atovaquone Increases Tumor Oxygenation and Inhibits Hypoxic Gene Expression in Patients with Non–Small Cell Lung Cancer

(2021) Michael Skwarski et al.   CLINICAL CANCER RESEARCH

Atovaquone: An antiprotozoal drug, suppresses primary and resistant breast tumor growth by inhibiting HER2/β-catenin signaling

(2019) Nehal Gupta et al.   MOLECULAR CANCER THERAPEUTICS

A prospective, multicenter DAHANCA study of hyperfractionated, accelerated radiotherapy for head and neck squamous cell carcinoma

(2019) Mette Saksø et al.   ACTA ONCOLOGICA

Targeting mitochondrial respiration as a therapeutic strategy for cervical cancer

(2018) Shenglan Tian et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Nitroimidazoles as hypoxic cell radiosensitizers and hypoxia probes: misonidazole, myths and mistakes

(2018) Peter Wardman   BRITISH JOURNAL OF RADIOLOGY

Oxidative Phosphorylation as an Emerging Target in Cancer Therapy

(2018) Thomas M. Ashton et al.   CLINICAL CANCER RESEARCH

Hypoxia imaging with 18F-FAZA PET/CT predicts radiotherapy response in esophageal adenocarcinoma xenografts

(2018) Elodie Melsens et al.   Radiation Oncology

LBA8_PRKEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)

(2018) B Burtness et al.   ANNALS OF ONCOLOGY

Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial

(2018) Hisham Mehanna et al.   LANCET

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial

(2018) Maura L Gillison et al.   LANCET

Clinical Advances of Hypoxia-Activated Prodrugs in Combination With Radiation Therapy

(2017) Ishna N. Mistry et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Imidazoles as potential anticancer agents

(2017) Imran Ali et al.   MedChemComm

Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent

(2016) M. Xiang et al.   BLOOD

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia

(2016) Thomas M. Ashton et al.   Nature Communications

Repurposing atovaquone: Targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells

(2016) Marco Fiorillo et al.   Oncotarget

Emerging drugs for head and neck cancer

(2015) Yihui Wen et al.   EXPERT OPINION ON EMERGING DRUGS

Epidemiology of Human Papillomavirus–Positive Head and Neck Squamous Cell Carcinoma

(2015) Maura L. Gillison et al.   JOURNAL OF CLINICAL ONCOLOGY

Human Papillomavirus–Associated Oropharyngeal Cancer: Defining Risk Groups and Clinical Trials

(2015) Aarti Bhatia et al.   JOURNAL OF CLINICAL ONCOLOGY

Human Papillomavirus–Negative Pharyngeal Cancer

(2015) Magnus T. Dillon et al.   JOURNAL OF CLINICAL ONCOLOGY

IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma

(2015) Mohamed A. Hassan Metwally et al.   RADIOTHERAPY AND ONCOLOGY

Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522

(2014) K. Kian Ang et al.   JOURNAL OF CLINICAL ONCOLOGY

Structural analysis of atovaquone-inhibited cytochrome bc1 complex reveals the molecular basis of antimalarial drug action

(2014) Dominic Birth et al.   Nature Communications

Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis

(2014) William W Wheaton et al.   eLife

Reprogramming Metabolism with Metformin Improves Tumor Oxygenation and Radiotherapy Response

(2013) V. E. Zannella et al.   CLINICAL CANCER RESEARCH

Phase II study of concomitant chemoradiotherapy with local hyperthermia and metronidazole for locally advanced fixed rectal cancer

(2013) Yu.A. Barsukov et al.   Colorectal Disease

Antimalarial pharmacology and therapeutics of atovaquone

(2013) G. L. Nixon et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

More Lessons Learned From the Suffocation of Hypoxia

(2010) K. Kian Ang   JOURNAL OF CLINICAL ONCOLOGY

Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer

(2010) K. Kian Ang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

(2009) James A Bonner et al.   LANCET ONCOLOGY

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients

(2009) Jean-Pierre Pignon et al.   RADIOTHERAPY AND ONCOLOGY

HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer

(2009) Pernille Lassen et al.   RADIOTHERAPY AND ONCOLOGY

Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies

(2008) Jan. B. Vermorken et al.   CANCER

Improved Survival of Patients With Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical Trial

(2008) C. Fakhry et al.   JNCI-Journal of the National Cancer Institute

Recent Advances in Head and Neck Cancer

(2008) Robert I. Haddad et al.   NEW ENGLAND JOURNAL OF MEDICINE